Please sign in to follow a disease.
Cytokinetics
Clinical trials sponsored by Cytokinetics, explained in plain language.
Biopharmaceutical company focused on muscle biology and cardiac muscle diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New heart failure pill shows promise in early trial Results expected Sep 2026 (estimated) May already have reported ↗
- New heart failure drug aims to cut hospitalizations and deaths Results expected Sep 2027 (estimated) May already have reported ↗
-
New drug aims to help kids with stiff heart muscle breathe easier
Disease control OngoingThis study tests a medicine called aficamten in children aged 12 to 18 with a heart condition that makes it hard for blood to pump out. The goal is to see if the drug can reduce pressure inside the heart and improve symptoms like shortness of breath. About 55 participants will re…
Phase 2/3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Heart drug aficamten tested for Long-Term safety in 900 patients
Disease control By invitation onlyThis study follows 900 people with hypertrophic cardiomyopathy who have already taken aficamten in earlier trials. Researchers want to see if the drug is safe and tolerable over a longer period. Participants take aficamten tablets daily, with regular clinic visits to monitor for …
Phase 2/3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New heart drug aficamten aims to boost exercise and quality of life in HCM patients
Symptom relief OngoingThis phase 3 trial tests whether aficamten, an oral drug, can improve quality of life and exercise capacity in 500 adults with symptomatic non-obstructive hypertrophic cardiomyopathy, a heart condition that makes the heart muscle thick and stiff. Participants receive either afica…
Phase 3 • Sponsor: Cytokinetics • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC